FILING ANALYSIS · THURSDAY, NOVEMBER 5
Cartesian Therapeutics, Inc. RNAC — 8-K: Results of Operations and Financial Condition
neutral
The company reported its Q3 2026 financial results and provided a business update, with a focus on the upcoming Phase 3 AURORA trial data readout and BLA filing for Descartes-08 in myasthenia gravis, as well as progress in other pipeline programs, and reported $124.7 million in cash and cash equivalents as of September 30, 2026.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →